Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Do genetic variations in the adenosine pathway affect patient response to methotrexate?

Nature Clinical Practice Rheumatology volume 2, pages 648–649 (2006)Cite this article

boxed-textWessels JAM et al. (2006) Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 54: 2830–2839

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cronstein BN (2006) Pharmacogenetics in the rheumatic diseases, from pret-a-porter to haute couture. Nat Clin Pract Rheumatol 2: 2–3

    Article  CAS  Google Scholar 

  2. Cronstein BN (2005) Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 57: 163–172

    Article  CAS  Google Scholar 

  3. Wessels JA et al. (2006) Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 54: 1087–1095

    Article  CAS  Google Scholar 

  4. Dervieux T et al. (2004) Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 50: 2766–2774

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Medicine, Pathology and Pharmacology in the Divisions of Clinical Pharmacology and Rheumatology of the Department of Medicine, New York University School of Medicine, New York, NY, USA

    Bruce N Cronstein

Authors
  1. Bruce N Cronstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruce N Cronstein.

Ethics declarations

Competing interests

Intellectual Property: The author has patents on use of adenosine A2A receptor agonists to promote wound healing and use of A2A receptor antagonists to inhibit fibrosis. The author also has patent on testing for SNPs in the adenosine A1 receptor in patients with fibromyalgia and patent on use of adenosine A1 receptor antagonists to treat osteoporosis and other diseases of bone.

Dr Cronstein has been a consultant for the following companies (within the past two years):

King Pharmaceutical (licensee of patents above)

Can Fite Biopharmaceuticals

Bristol-Myers Squibb

Cellzome

Prometheus Laboratories

Regeneron (Westat, DSMB)

Sepracor

Amgen

Endocyte

HonorarialSpeakers' Bureaus

Tap Pharmaceuticals

Dr Cronstein has stock in the following companies:

Can Fite Biopharmaceuticals received for membership in Scientific Advisory Board.

The author has received grants from the following company:

King Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cronstein, B. Do genetic variations in the adenosine pathway affect patient response to methotrexate?. Nat Rev Rheumatol 2, 648–649 (2006). https://doi.org/10.1038/ncprheum0353

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0353

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing